Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline

Practical Radiation Oncology

Volumn 6, Issue 4, 2016, Pages 217-225

  Cabrera, Alvin R ^a   Kirkpatrick, John P ^b   Fiveash, John B ^c   Shih, Helen A ^d   Koay, Eugene J ^e   Lutz, Stephen ^f   Petit, Joshua ^g   Chao, Samuel T ^h   Brown, Paul D ^e   Vogelbaum, Michael ^h   Reardon, David A ⁱ   Chakravarti, Arnab ^j   Wen, Patrick Y ⁱ   Chang, Eric ^k  

^a Group Health Research   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c The University of Alabama at Birmingham   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f Blanchard Valley Regional Cancer Center   (United States)

^g UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

^j OHIO STATE UNIVERSITY   (United States)

^k UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARMUSTINE; GLUCOCORTICOID; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ADJUVANT THERAPY; AGE; ARTICLE; BRACHYTHERAPY; BRAIN RADIATION; BRAIN SURGERY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; COGNITIVE DEFECT; CONSENSUS DEVELOPMENT; EVENT FREE SURVIVAL; EVIDENCE BASED PRACTICE; EXTERNAL BEAM RADIOTHERAPY; GLIOBLASTOMA; HEMATOLOGIC DISEASE; HUMAN; HYPOFRACTIONATED RADIOTHERAPY; INDIVIDUALIZATION; KARNOFSKY PERFORMANCE STATUS; MEDICAL SOCIETY; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NAUSEA AND VOMITING; OVERALL SURVIVAL; PATIENT CARE; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN METHYLATION; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RE-IRRADIATION; STEREOTACTIC RADIOSURGERY; SYSTEMATIC REVIEW (TOPIC); TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR BIOPSY; UNITED STATES; BRAIN NEOPLASMS; MALE; PROSPECTIVE STUDY;

BRAIN NEOPLASMS; DOSE FRACTIONATION; GLIOBLASTOMA; GUIDELINES AS TOPIC; HUMANS; MALE; PROSPECTIVE STUDIES; UNITED STATES;

EID: 84971350170     PISSN: 18798500     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prro.2016.03.007     Document Type: Article

References (46)

1. Qaseem A., Snow V., Owens D.K., Shekelle P. The development of clinical practice guidelines and guidance statements of the American College of Physicians: Summary of methods. Ann Intern Med 2010, 153:194-199.
2. Walker M.D., Alexander E., Hunt W.E., et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978, 49:333-343.
3. Walker M.D., Green S.B., Byar D.P., et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980, 303:1323-1329.
4. Walker M.D., Strike T.A., Sheline G.E. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979, 5:1725-1731.
5. Kristiansen K., Hagen S., Kollevold T., et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: A prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981, 47:649-652.
6. Sandberg-Wollheim M., Malmstrom P., Stromblad L.G., et al. A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4. Cancer 1991, 68:22-29.
7. Laperriere N., Zuraw L., Cairncross G. Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site G. Radiotherapy for newly diagnosed malignant glioma in adults: A systematic review. Radiother Oncol 2002, 64:259-273.
8. Keime-Guibert F., Chinot O., Taillandier L., et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med 2007, 356:1527-1535.
9. Stupp R., Hegi M.E., Mason W.P., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466.
10. Taphoorn M.J., Stupp R., Coens C., et al. Health-related quality of life in patients with glioblastoma: A randomised controlled trial. Lancet Oncol 2005, 6:937-944.
11. Athanassiou H., Synodinou M., Maragoudakis E., et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 2005, 23:2372-2377.
12. Szczepanek D., Marchel A., Moskala M., Krupa M., Kunert P., Trojanowski T. Efficacy of concomitant and adjuvant temozolomide in glioblastoma treatment. A multicentre randomized study. Neurol Neurochir Pol 2013, 47:101-108.
13. Kocher M., Frommolt P., Borberg S.K., et al. Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma. Strahlenther Onkol 2008, 184:572-579.
14. Hart M.G., Garside R., Rogers G., Stein K., Grant R. Temozolomide for high grade glioma. Cochrane Database Syst Rev 2013, 4:CD007415.
15. Chinot O.L., Wick W., Mason W., et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014, 370:709-722.
16. Gilbert M.R., Dignam J.J., Armstrong T.S., et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014, 370:699-708.
17. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
18. Bleehen N.M., Stenning S.P. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer 1991, 64:769-774.
19. Nelson D.F., Diener-West M., Horton J., Chang C.H., Schoenfeld D., Nelson J.S. Combined modality approach to treatment of malignant gliomas--re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: A joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monogr 1988, 279-284.
20. Prados M.D., Wara W.M., Sneed P.K., et al. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001, 49:71-77.
21. Souhami L., Seiferheld W., Brachman D., et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 2004, 60:853-860.
22. Lawrence Y.R., Li X.A., el Naqa I., et al. Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys 2010, 76:S20-S27.
23. Reddy K., Damek D., Gaspar L.E., et al. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2012, 84:655-660.
24. Yoon S.M., Kim J.H., Kim S.J., et al. Hypofractionated intensity-modulated radiotherapy using simultaneous integrated boost technique with concurrent and adjuvant temozolomide for glioblastoma. Tumori 2013, 99:480-487.
25. Curran W.J., Scott C.B., Horton J., et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993, 85:704-710.
26. Roa W., Brasher P.M., Bauman G., et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: A prospective randomized clinical trial. J Clin Oncol 2004, 22:1583-1588.
27. Malmstrom A., Gronberg B.H., Marosi C., et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: The Nordic randomised, phase 3 trial. Lancet Oncol 2012, 13:916-926.
28. Wick W., Platten M., Meisner C., et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: The NOA-08 randomised, phase 3 trial. Lancet Oncol 2012, 13:707-715.
29. Gallego Perez-Larraya J., Ducray F., Chinot O., et al. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: An ANOCEF phase II trial. J Clin Oncol 2011, 29:3050-3055.
30. Minniti G., Lanzetta G., Scaringi C., et al. Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys 2012, 83:93-99.
31. Minniti G., Scaringi C., Baldoni A., et al. Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide. Int J Radiat Oncol Biol Phys 2013, 86:285-291.
32. Gardner W.J. Removal of the right cerebral hemisphere for infiltrating glioma. JAMA 1933, 101(11):823-826.
33. Wallner K.E., Galicich J.H., Krol G., Arbit E., Malkin M.G. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 1989, 16:1405-1409.
34. Gaspar L.E., Fisher B.J., Macdonald D.R., et al. Supratentorial malignant glioma: Patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys 1992, 24:55-57.
35. Shapiro W.R., Green S.B., Burger P.C., et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg 1989, 71:1-9.
36. Sharma R.R., Singh D.P., Pathak A., et al. Local control of high-grade gliomas with limited volume irradiation versus whole brain irradiation. Neurol India 2003, 51:512-517.
37. Kelly P.J., Daumas-Duport C., Scheithauer B.W., Kall B.A., Kispert D.B. Stereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clin Proc 1987, 62:450-459.
38. Chang E.L., Akyurek S., Avalos T., et al. Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma. Int J Radiat Oncol Biol Phys 2007, 68:144-150.
39. Minniti G., Amelio D., Amichetti M., et al. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother Oncol 2010, 97:377-381.
40. Gebhardt B.J., Dobelbower M.C., Ennis W.H., Bag A.K., Markert J.M., Fiveash J.B. Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide. Radiat Oncol 2014, 9:130.
41. Kiebert G.M., Curran D., Aaronson N.K., et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: Results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group. Eur J Cancer 1998, 34:1902-1909.
42. Gondi V., Mehta M., Pugh S., et al. Memory preservation with conformal avoidance of the hippocampus during whole-brain radiotherapy (WBRT) for patients with brain metastases: Primary endpoint results of RTOG 0933 [abstract]. Int J Radiat Oncol Biol Phys 2013, 87:1186.
43. Carson K.A., Grossman S.A., Fisher J.D., Shaw E.G. Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol 2007, 25:2601-2606.
44. Shaw E., Scott C., Souhami L., et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: Final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys 2000, 47:291-298.
45. Gutin P.H., Iwamoto F.M., Beal K., et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2009, 75:156-163.
46. Cabrera A.R., Cuneo K.C., Desjardins A., et al. Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: A prospective trial. Int J Radiat Oncol Biol Phys 2013, 86:873-879.